Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors.
Sausville E, Lorusso P, Carducci M, Carter J, Quinn MF, Malburg L, Azad N, Cosgrove D, Knight R, Barker P, Zabludoff S, Agbo F, Oakes P, Senderowicz A.
Sausville E, et al. Among authors: lorusso p.
Cancer Chemother Pharmacol. 2014 Mar;73(3):539-49. doi: 10.1007/s00280-014-2380-5. Epub 2014 Jan 22.
Cancer Chemother Pharmacol. 2014.
PMID: 24448638
Free PMC article.
Clinical Trial.